early-cancer-detection
(6)
ARNA Genomics US Inc.
ARNA Genomics US Inc. is a San Francisco-based biotechnology company developing multiomics liquid-biopsy technology for early cancer detection. Its lead assay, ARNA Breast, analyzes cell-free DNA and plasma enzyme activity from a routine blood draw to flag early-stage breast cancer, with proof-of-concept studies reporting sensitivity above 90%. Founded in 2013 and led by CEO Egor Melnikov, the company raised a $3.5M Series A in 2020 to fund clinical validation.
Harae Dx Corp.
Harae Dx Corp. is a Pleasanton, California medical device startup building what it calls the world's smallest portable, automated system for early cancer detection. Founded in 2021 by serial medtech entrepreneur Sanjeev Saxena, the company pairs a proprietary lab-on-a-disc centrifugal microfluidic platform with a biomarker panel exclusively licensed from Lawrence Livermore National Laboratory to deliver a non-invasive early breast cancer test that returns results in roughly 30 minutes - without shipping samples to a third-party lab. Backed by SOSV/HAX and Fusion Fund, Harae Dx aims to make low-cost cancer screening portable enough to run at the point of care.
Human Longevity, Inc.
Human Longevity, Inc. is a San Diego- and South San Francisco-based genomics and precision-health company founded in 2013 by genome-sequencing pioneer J. Craig Venter, Peter Diamandis, and Robert Hariri. It pairs clinical-grade whole genome sequencing with whole-body MRI, hundreds of blood biomarkers, and AI analytics - delivered through its Health Nucleus platform - to detect cancer, cardiovascular disease, and other age-related conditions before symptoms appear. After a decade building one of the world's largest longitudinal genotype-phenotype datasets, the company in 2026 launched a $599 clinical-grade whole genome report and spun out Human Life Foundation Models, Inc. to build large-scale AI foundation models for longevity science.
ClearNote Health
ClearNote Health is a San Diego molecular diagnostics company building non-invasive, blood-based tests that detect high-mortality cancers early, when treatment works best. Spun out of Stephen Quake's Stanford lab in 2016 (originally as Bluestar Genomics), it pairs a proprietary 5-hydroxymethylcytosine (5hmC) epigenomic platform with cell-free DNA analysis and machine learning. Its flagship Avantect Pancreatic Cancer Test targets high-risk patients - including adults 50+ newly diagnosed with type 2 diabetes - and the company is extending the approach to ovarian and multi-cancer detection.
Clairity, Inc.
Clairity is a Boston-based healthtech company that built Clairity Breast, the first FDA-authorized AI platform that predicts a woman's five-year risk of breast cancer directly from a routine screening mammogram. Founded by Harvard radiologist Dr. Connie Lehman, the company turns images already sitting in the medical record into a forward-looking risk score, aiming to move breast care from late-stage detection toward early, equitable prevention.
Prenuvo
Prenuvo runs a chain of clinics built around a 60-minute whole-body MRI designed to spot cancer, aneurysms and hundreds of other conditions before symptoms show up. Founded by Andrew Lacy and radiologist Raj Attariwala, the company is trying to drag American healthcare from reactive to preventive, one scan at a time.